High-Throughput Assay Development for Non-Nicotine Tobacco Components
High-Throughput Assay Development for Non-Nicotine Tobacco Components
批准号:
8660057
负责人:
PAUL WHITEAKER
金额:
$23.25万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2015-05-31
关键词:
AddressAdoptedAffectAreaBehavioralBiological AssayCell LineChemicalsClinicCollectionCommunitiesConsensus SequenceDataDependenceDyesEligibility DeterminationEngineeringEnsureFamilyFamily Smoking Prevention and Tobacco Control ActFluorescenceGoalsHumanLaboratoriesMediator of activation proteinMembrane PotentialsMonitorNamesNicotineNicotinic ReceptorsPhysiologicalPopulationProceduresProductionPublishingRegulationResearchResourcesScreening ResultSmokeSmoking PreventionStagingTechniquesTestingTherapeuticTobaccoTobacco DependenceTobacco Use CessationTobacco useUnited States Food and Drug AdministrationUnited States National Institutes of HealthVariantWritingaddictionassay developmentbasedesignexperiencefollow-uphigh throughput screeninginnovationinsightmembernicotinic receptor alpha4beta2novelprogramspublic health relevancereceptorresponsescreeningsmall molecule librariestobacco control
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): A pair of High Throughput Screening (HTS) assays suitable for identifying non-nicotine tobacco product compounds with activity at ¿3¿4 and ¿4¿2 nicotinic receptors is proposed. Two Specific Aims are described: 1. HTS-ready assays will be established and optimized for a pair of existing, highly-functional, monoclonal cell lines. One is stably transfected with ¿3¿4-, the other with ¿4¿2- nicotinic acetylcholine receptors (nAChRs). Both membrane-potential and Ca2+ dye fluorescence approaches are suitable and the approach which can be refined to provide the most robust and reliable results will be adopted for Aim 2. 2. The optimized assays will be configured for HTS conditions. An overall screening workflow is proposed, and will be applied to each of the optimized ¿3¿4 and ¿4¿2 HTS-ready assays. This workflow incorporates secondary orthogonal- potency-, and selectivity-counter-screening protocols to identify and discard false positives, and to characterize confirmed candidates, from the initial screens. Already-available assays suitable for orthogonal- and counter-screening, using different activities than the primary screen, are described. We will generate proof-of-principle data for each fully-configured assay using a pilot screen of ~2400 structurally-diverse test compounds. Relevance of this proposal to PAR-12-266, and the Family Smoking Prevention and Tobacco Control Act (FSPTCA): As detailed in the Specific Aims, Significance and Innovation sections, this proposal will provide a set of validated assays targeting nAChR subtypes tied to use of, and dependence on, tobacco products. The resulting screens will produce impact by accelerating progress on two stated goals of PAR-12-266: 1) "Reducing Addiction - understanding ... other constituents and components beyond nicotine that affect addiction of combustible and non-combustible tobacco products." 2) "Diversity of Tobacco Products - understanding the constituents, components, ingredients, additives, and design features; ... of conventional and new and emerging tobacco products." They will also address a specific research area of the FDA Center for Tobacco Products (http://www.fda.gov/downloads/TobaccoProducts/NewsEvents/UCM293998.pdf; #15; "What high-throughput screens can be developed and/or used to evaluate compounds in tobacco products and smoke that may affect addiction (e.g., act on nicotinic or dopaminergic receptors...etc.)?). Availability of this suite of screens will also advance priorities of the FSPTCA. Tobacco product components identified by such screens will be valuable leads for follow-up studies to understand their relevance to tobacco use and dependence, and their precise mechanisms of action. These studies would provide impact through new scientific insights and potentially by revealing novel tobacco-cessation therapeutic avenues/targets. Compounds identified by these screens may also be candidates for regulation under the FSPTCA.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.slasd.2021.10.001
发表时间:
2022-01
期刊:
SLAS discovery : advancing life sciences R & D
影响因子:
--
作者:
[Kassner M, Eaton JB, Tang N, Petit JL, Meurice N, Yin HH, Whiteaker P]
通讯作者:
Whiteaker P
Relevance of α-Conotoxin MII Sensitive Nicotinic Receptor Subtypes to Nicotine Addiction
-
批准号:10600540
-
项目类别:
-
资助金额:$55.0万
-
财政年份:2022
-
负责人:PAUL WHITEAKER
-
依托单位:
Relevance of α-Conotoxin MII Sensitive Nicotinic Receptor Subtypes to Nicotine Addiction
-
批准号:9212601
-
项目类别:
-
资助金额:$56.72万
-
财政年份:2017
-
负责人:PAUL WHITEAKER
-
依托单位:
High-Throughput Assay Development for Non-Nicotine Tobacco Components
-
批准号:8576344
-
项目类别:
-
资助金额:$23.01万
-
财政年份:2013
-
负责人:PAUL WHITEAKER
-
依托单位:
HTS Assay Development for alpha6/3beta2beta3 Subtype Nicotinic Receptors
-
批准号:8212661
-
项目类别:
-
资助金额:$25.4万
-
财政年份:2011
-
负责人:PAUL WHITEAKER
-
依托单位:
Construction and Expression of Concatemeric alpha6beta2* Nicotinic Acetycholine R
-
批准号:7641663
-
项目类别:
-
资助金额:$19.13万
-
财政年份:2009
-
负责人:PAUL WHITEAKER
-
依托单位:
Immunochemical Protocols for Nicotinic Receptors
-
批准号:6902770
-
项目类别:
-
资助金额:$18.61万
-
财政年份:2005
-
负责人:PAUL WHITEAKER
-
依托单位:
Immunochemical Protocols for Nicotinic Receptors
-
批准号:7031028
-
项目类别:
-
资助金额:$21.82万
-
财政年份:2005
-
负责人:PAUL WHITEAKER
-
依托单位:
Alpha-Conotoxin MII: A Selective Nicotinic Receptor Probe
-
批准号:8116617
-
项目类别:
-
资助金额:$35.53万
-
财政年份:1999
-
负责人:PAUL WHITEAKER
-
依托单位:
Alpha-Conotoxin MII: A Selective Nicotinic Receptor Probe
-
批准号:7317703
-
项目类别:
-
资助金额:$35.18万
-
财政年份:1999
-
负责人:PAUL WHITEAKER
-
依托单位:
Alpha-Conotoxin MII: A Selective Nicotinic Receptor Probe
-
批准号:7891168
-
项目类别:
-
资助金额:$35.66万
-
财政年份:1999
-
负责人:PAUL WHITEAKER
-
依托单位:
Alpha-Conotoxin MII: A Selective Nicotinic Receptor Probe
-
批准号:7681686
-
项目类别:
-
资助金额:$35.06万
-
财政年份:1999
-
负责人:PAUL WHITEAKER
-
依托单位:
海外基金